Eva Schmid
Research Interests
Eva Schmid has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Aiden Haghikia
Department of Neurology, St. Josef-Hospital Bochum, Ruhr-University Bochum, Bochum, Germany
1 shared publication - Arne Gessner
Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
1 shared publication - Cezmi A. Akdis
Swiss Institute of Allergy and Asthma Research (SIAF), University Zurich Davos Switzerland
1 shared publication - Daniele Mauro
Dipartimento di Medicina di Precisione, Università della Campania “Luigi Vanvitelli”, Naples, Italy
1 shared publication - Fabian Schälter
Department of Internal Medicine 3, Rheumatology and Immunology
1 shared publication - Felix Beyer
Institute of Biochemistry, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany
1 shared publication
Latest Publications
- Open Access
- 10 July 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (18)
Gut-specific histamine 3 receptor signaling orchestrates microglia-dependent resolution of peripheral inflammation
Chronic inflammatory diseases like rheumatoid arthritis (RA) have been described to cause CNS activation. Less is known about environmental factors that enable the CNS to suppress peripheral inflammation in RA. Here, we identified gut microbiota–derived histamine as such a factor. We showed that low levels of histamine activate the enteric nervous system, increase inhibitory neurotransmitter concentrations in the spinal cord, and restore homeostatic microglia, thereby reducing inflammation in the joints. We found that elective histamine 3 receptor (H3R) signaling in the intestine was critical for this effect, as systemic and intrathecal application did not show effects. Microglia depletion or pharmacological silencing of local nerve fibers impaired oral H3R agonist–induced pro-resolving effects on arthritis. Moreover, therapeutic supplementation of the short-chain fatty acid propionate revealed one way to expand local intestinal histamine concentrations in mice and humans. Thus, we define a gut/CNS/joint axis pathway where microbiota-derived histamine initiates the resolution of arthritis via the CNS.
- 10 July 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (18)
Open AccessGut-specific histamine 3 receptor signaling orchestrates microglia-dependent resolution of peripheral inflammation
Chronic inflammatory diseases like rheumatoid arthritis (RA) have been described to cause CNS activation. Less is known about environmental factors that enable the CNS to suppress peripheral inflammation in RA. Here, we identified gut microbiota–derived histamine as such a factor. We showed that low levels of histamine activate the enteric nervous system, increase inhibitory neurotransmitter concentrations in the spinal cord, and restore homeostatic microglia, thereby reducing inflammation in the joints. We found that elective histamine 3 receptor (H3R) signaling in the intestine was critical for this effect, as systemic and intrathecal application did not show effects. Microglia depletion or pharmacological silencing of local nerve fibers impaired oral H3R agonist–induced pro-resolving effects on arthritis. Moreover, therapeutic supplementation of the short-chain fatty acid propionate revealed one way to expand local intestinal histamine concentrations in mice and humans. Thus, we define a gut/CNS/joint axis pathway where microbiota-derived histamine initiates the resolution of arthritis via the CNS.